Sandbox/pyelo: Difference between revisions
< Sandbox
Gerald Chi- (talk | contribs) No edit summary |
Gerald Chi- (talk | contribs) No edit summary |
||
Line 18: | Line 18: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Gentamicin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Tobramycin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Amikacin]] 20 mg/kg IV x 1 dose''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Gentamicin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Tobramycin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Amikacin]] 20 mg/kg IV x 1 dose''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 1''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 160/800 mg PO q12h x 14 days ''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 160/800 mg PO q12h x 14 days''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS <SMALL>'''(if TMP/SMZ resistance unknown)'''</SMALL> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS <SMALL>'''(if TMP/SMZ resistance unknown)'''</SMALL> | ||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Gentamicin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Tobramycin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Amikacin]] 20 mg/kg IV x 1 dose''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 2''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amoxicillin-clavulanate potassium|Amoxicillin–Clavulanate]] 500/125 mg PO q12h x 14 days'''''<BR> OR <BR> ▸ '''''[[Amoxicillin-clavulanate potassium|Amoxicillin–Clavulanate]] 250/125 mg PO q8h x 5–7 days'''''<BR> OR <BR> ▸ '''''[[Cefaclor]] 500 mg PO q8h x 7 days''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Gentamicin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Tobramycin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Amikacin]] 20 mg/kg IV x 1 dose''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 g IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Gentamicin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Tobramycin]] 7 mg/kg IV x 1 dose'''''<BR> OR <BR> ▸ '''''[[Amikacin]] 20 mg/kg IV x 1 dose''''' | ||
Line 34: | Line 42: | ||
{| style="background: #FFFFFF;" | {| style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: | {| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Acute Pyelonephritis, Inpatient}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Acute Pyelonephritis, Inpatient}} | ||
|- | |- |
Revision as of 01:34, 23 February 2014
|
|